Combined Cancer Immunotheranostic Nanomedicines: Delivery Technologies and Therapeutic Outcomes.
Tasneem A NasserRawan AdelAbdelrahman BadrMohamed TelebAdnan A BekhitKadria A ElkhodairyAhmed S AbdelhamidAhmed O ElzoghbyPublished in: ACS omega (2023)
Cancer is among the main causes of mortality all over the world. The delayed diagnosis is directly related to the decrease in survival rate. The use of immunotherapy has dramatically changed the treatment outcomes of different types of cancers. However, many patients still do not respond to immunotherapies, and many also suffer from severe immune-related side effects. Recent advances in the fields of nanomedicine bioengineering and in particular imaging offered new approaches which can enhance not only the safety but also the efficacy of immunotherapy. Theranostics has showed great progress as a branch of medicine which integrates both diagnosis and therapy in a single system. The outcomes from animal studies demonstrated an improvement in the diagnostic and immunotherapeutic potential of nanoparticles within the theranostic framework. Herein, we discuss the most recent developments in the application of nanotheranostics for combining tumor imaging and cancer immunotherapies.
Keyphrases
- papillary thyroid
- squamous cell
- high resolution
- end stage renal disease
- lymph node metastasis
- ejection fraction
- type diabetes
- chronic kidney disease
- squamous cell carcinoma
- newly diagnosed
- early onset
- metabolic syndrome
- coronary artery disease
- prognostic factors
- skeletal muscle
- mass spectrometry
- peritoneal dialysis
- smoking cessation
- risk assessment
- insulin resistance
- drug induced
- mesenchymal stem cells
- free survival